Prostate Cancer | Specialty

The OncLive Prostate Cancer condition center page is a comprehensive resource for clinical news and expert insights on how to approach treatment for patients with nonmetastatic, castration-resistant, or castration-sensitive prostate cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, ongoing research, and treatment advances with androgen receptor inhibitors, PARP inhibitors, and more in prostate cancer.

PSMA as a Biomarker in Advanced Prostate Cancer

July 23rd 2021

Dr Scott T. Tagawa describes what prostate-specific membrane antigen (PSMA) is and explains its evolving role as a diagnostic, prognostic and therapeutic target in patients with advanced prostate cancer.

Dr. Burnham on Closing the Gap in Health Disparities in Prostate Cancer

July 22nd 2021

Leanne Burnham, PhD, discusses the need to close the gap in health disparities in prostate cancer.

New Tool Could Help Predict Outcomes with 177Lu-PSMA in Metastatic Castration-Resistant Prostate Cancer

July 22nd 2021

A new prognostic tool, the nomogram, has demonstrated the ability to predict outcomes following treatment with lutetium-177 prostate-specific membrane antigen in patients with metastatic castration-resistant prostate cancer, and could potentially be used to inform future trial designs and clinical decisions.

Dr. Lyou on Emerging Biomarkers in Prostate Cancer

July 19th 2021

Yung Lyou, MD, PhD, discusses emerging biomarkers in prostate cancer.

Ipatasertib/Abiraterone Data Published in Lancet Underscore the Combo’s Frontline Potential in PTEN-Loss mCRPC

July 19th 2021

Ipatasertib plus abiraterone acetate and prednisone demonstrated a significant improvement in radiographic progression-free survival vs placebo plus abiraterone in patients with metastatic castration-resistant prostate cancer with PTEN loss, according to findings from the ongoing phase 3 IPATential150 trial now published in The Lancet.

Dr. Lyou on Sequencing Apalutamide in Prostate Cancer

July 16th 2021

Yung Lyou, MD, PhD, discusses optimal sequencing with apalutamide in prostate cancer.

Darolutamide/ADT Significantly Improves OS in Nonmetastatic CRPC, Irrespective of Crossover

July 15th 2021

Neal Shore, MD, FACS, discusses the impact of crossover from placebo to darolutamide on OS benefit in patients with nmCRPC enrolled to the ARAMIS trial, and next steps for the androgen receptor inhibitor.

Dr. Burnham on Health Disparities in Prostate Cancer

July 14th 2021

Leanne Burnham, PhD, discusses health disparities in prostate cancer.

Addition of Focal Boost to Intraprostatic Lesions in EBRT Improves Biochemical DFS in Localized Prostate Cancer

July 14th 2021

The addition of a focal boost to the intraprostatic lesion was found to improve biochemical disease-free survival in patients undergoing treatment with external beam radiotherapy for localized intermediate- and high-risk prostate cancer.

Dr. Sereti on Addressing an Unmet Need With NOV202/Olaparib in BRCA1/2-Mutated Prostate Cancer

July 14th 2021

Evangelia Sereti, MSc, PhD, discusses the unmet need addressed with the addition of NOV202 to olaparib in BRCA1/2-mutated prostate cancer.

Dr. Tagawa on the Utility of Radium-223 in Prostate Cancer

July 14th 2021

Scott Tagawa, MD, MS, FACP, discuses the benefits of radium-223 dichloride in prostate cancer.

Dr. Dreicer on the Initial Findings With Sabizabulin in mCRPC

July 13th 2021

Robert Dreicer, MD, discusses the initial findings with sabizabulin in metastatic castration-resistant prostate cancer.

Dr. Wagaskar on Potential Explanations for the Obesity Paradox in Prostate Cancer

July 12th 2021

Vinayak G. Wagaskar, MBBS, discusses potential explanations for a paradoxical relationship between obesity and outcomes observed in prostate cancer.

Dr. Sereti on the Next Steps for NOV202 Plus Olaparib in BRCA1/2-Mutated Prostate Cancer

July 12th 2021

Evangelia Sereti, MSc, PhD, discusses the next steps with the combination of NOV202 and olaparib in BRCA1/2-mutated prostate cancer.

Darolutamide Demonstrates Favorable Tolerability in Nonmetastatic CRPC

July 12th 2021

Treatment with darolutamide induced a low cumulative incidence of hormone treatment–related adverse effects that was comparable to treatment with placebo in patients with nonmetastatic castration-resistant prostate cancer, according to findings from a safety analysis of the phase 3 ARAMIS trial.

Abiraterone/Prednisone Combo Linked With Improvements in Fatigue and QoL, But Worsening Metabolic Changes in mCRPC

July 12th 2021

Abiraterone acetate plus prednisone should be considered as the first treatment choice for patients with newly diagnosed metastatic castration-resistant prostate cancer if fatigue is a concern.

Darolutamide Crossover Leads to High PSA Response in Nonmetastatic CRPC

July 12th 2021

Eighty-five percent of patients with nonmetastatic castration-resistant prostate cancer who crossed over from placebo to darolutamide in the phase 3 ARAMIS trial experienced a maximum prostate-specific antigen decline of at least 50% at any time of crossover.

Apalutamide Plus ADT Improves Survival Regardless of Disease Volume in mCSPC

July 12th 2021

Investigators demonstrated that the benefit of androgen deprivation therapy was extended with the addition of apalutamide for patients with metastatic castration-sensitive prostate cancer regardless of disease volume.

Neoadjuvant Apalutamide Does Not Interfere With Robotic Prostatectomy

July 12th 2021

Intense androgen receptor inhibition with neoadjuvant apalutamide did not complicate robotic prostatectomy surgical outcomes.

Patients With Urological Cancer and COVID-19 Undergoing Elective Surgery at Higher Risk for Mortality

July 10th 2021

Patients with a urological cancer who were also infected with COVID-19 and undergoing elective surgery for their disease, were found to have a significantly higher likelihood of experiencing respiratory complications and mortality than those without the virus.